diabetic macular edema (DME)

^[1]

Introduction

intravitreal VEGF inhibitor improves vision in patients with diabetic macular edema^[1]
- intravitreal ranibizumab only if:
  - the eye has a central retinal thickness of >= 400 uM at the start of treatment^[1] (NICE)

fluocinolone acetonide intravitreal implant is not recommended^[1] (NICE)
cost to patients per intravitreal dose (2015)^[1]
- bevacizumab: $50
- ranibizumab: $1,200
- aflibercept: $1,950
- brolucizumab: ?

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 Young K, Sadough S Anti-VEGF Agents Tied to Improved Visual Acuity in Diabetic Macular Edema Physician's First Watch, Feb 19, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351